Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COED: Ozurdex + Eylea in DME
NCT03984110Phase 4Completed
- Sponsor
- Texas Retina Associates
- Start
- Jun 2019
- Primary completion
- Oct 2022
- Modality
- Implantable Devices, Implantable Hydrogels, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ozurdex in diabetic macular edema (DME), sponsored by Texas Retina Associates. Started Jun 2019; status: completed.
02
Drugs
ozurdex
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT03984110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03984110.